KDR and neoplasm: Ramucirumab (Cyramza®) developed jointly by ImClone Systems (New York City, NY, USA) and Dyax (Cambridge, MA, USA) is a fully human monoclonal IgG1 antibody that binds to the ECD of human VEGFR2, which is a key receptor that mediates angiogenesis and is highly expressed in not only tumor microvessels but also malignant tumors.